骨肉瘤患者外周血Tc17细胞的比例及其临床意义

目的] 分析Tc17细胞在骨肉瘤患者外周血中的分布及其临床意义.方法] 检测41例骨肉瘤患者及17例健康人外周血中Tc17细胞的比例及血浆中白细胞介素-17(IL-17)浓度,分析Tc17细胞比例与IL-17浓度及肿瘤临床分期的关系.结果] 与正常对照组(0.72±0.46)% 相比,骨肉瘤患者外周血中Tc17细胞比例(3.18±1.99)%明显增加,两者相比较差异有显著性(P<0.01);骨肉瘤患者外周血血浆中IL-17浓度显著高于健康对照组;Tc17细胞水平与IL-17浓度、骨肉瘤肿瘤临床分期无明显相关性(P<0.05).结论] 骨肉瘤患者外周血Tc17细胞水平明显升高,可能与骨肉瘤患者肿瘤免疫功能低下及肿瘤发生发展密切相关.

Prevalence of Tc17 Cells in the Peripheral Blood of Patients with Osteosarcoma and its Clinical Significance

Objective]To investigate the prevalence of Tc17 cells in the peripheral blood of patients with osteosarcoma.Methods]Flow cytometry was used to evaluate the prevalence of Tc17 cells in the peripheral blood of 41 patients with osteosarcoma and 17 healthy people.In addition, the concentration of IL-17 was measured.The relationship between peripheral blood Tc17 cell level with the concentration of IL-17 and tumor stage was determined statistically.Results]The prevalence of Tc17 cells in the peripheral blood of patients with osteosarcoma (3.18±1.99%) increased greatly with increased levels of IL-17, compared with the normal control subjects (0.72±0.46%).The differences were statistically significant (P<0.01).The percentage of Tc17 cells was not associated with the concentration of IL-17 or the stages of osteosarcoma.Conclusion]The prevalence of Tc17 cells is increased in the peripheral blood of patients with osteosarcoma.These cells may negatively regulate antitumor immune response of patients.